GH RESEARCH PLC
NASDAQ: GHRS (GH Research PLC)
Last update: 3 hours ago11.18
-0.21 (-1.84%)
| Previous Close | 11.39 |
| Open | 11.18 |
| Volume | 138,683 |
| Avg. Volume (3M) | 245,308 |
| Market Cap | 693,474,176 |
| Price / Book | 3.88 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.750 |
| Total Debt/Equity (MRQ) | 0.35% |
| Current Ratio (MRQ) | 17.23 |
| Operating Cash Flow (TTM) | -42.28 M |
| Levered Free Cash Flow (TTM) | -30.45 M |
| Return on Assets (TTM) | -15.15% |
| Return on Equity (TTM) | -19.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | GH Research PLC | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 2.13 |
|
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 33.88% |
| % Held by Institutions | 52.11% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 32.00 (Guggenheim, 186.23%) | Buy |
| 32.00 (Stifel, 186.23%) | Buy | |
| Median | 31.50 (181.75%) | |
| Low | 14.00 (Cantor Fitzgerald, 25.22%) | Buy |
| Average | 27.25 (143.74%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 11.59 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 13 Mar 2025 | 32.00 (186.23%) | Buy | 10.88 |
| RBC Capital | 07 Mar 2025 | 31.00 (177.28%) | Buy | 10.50 |
| Stifel | 27 Feb 2025 | 32.00 (186.23%) | Buy | 10.65 |
| Cantor Fitzgerald | 13 Feb 2025 | 14.00 (25.22%) | Buy | 14.31 |
| Date | Type | Details |
|---|---|---|
| 27 Feb 2025 | Announcement | GH Research Reports Full Year 2024 Financial Results and Provides Business Updates |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |